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formation of lymphatics. Hypoxia induced 
by vessel damage and  brosis is another cru-
cial factor involved in the pathogenesis of 
diabetic renal disease damage. It is known 
from the oncology  eld that the invasion and 
migration of microvascular endothelial 
cells is increased during hypoxia. 13 
 Sakamoto  et al. 14 (this issue) investigated 
the expression of D2-40 – positive lymphatic 
vessels, with special interest in VEGF-C, a 
crucial mediator of lymphan-giogenesis in 
chronic renal disease. * ey meticulously 
mapped the presence of lymphatic vessels in 
a wide range of renal diseases using D2-40 
and VEGF-C antibodies. * ey con rmed 
the absence of corticomedullary lymphatics 
in control kidneys but found lymphangio-
genesis in tubulointerstitial fibrosis and 
in9 ammatory interstitial areas in various 
renal diseases. * ese vessels were o4 en  lled 
with mononuclear cells. Interestingly, lym-
phangiogenesis and VEGF-C expression 
were elevated in diabetic nephropathy as 
compared with other renal diseases. 
 * e study is a solid base for continuing 
research, as several questions remain and 
have to be resolved. For instance, do glucose 
and AGEs have any e: ect on the produc-
tion of VEGF-C by resident glomerular cells 
and the subsequent growth of lymphatic 
vessels? * is question can easily be resolved 
in an  in vitro setup. What are the other 
signals involved in lymphangiogenesis? Do 
components of the extracellular matrix 
 per se have any e: ect on lymphangiogenesis? 
And what about ischemia, a central event in 
chronic renal disease and renal transplanta-
tion; does it provoke VEGF-C expression and 
lymphangiogenesis? What is the role of cy -
closporine in the formation of lymphatics? 
 Despite all these questions, this 
elegant, elaborate study of Sakamoto 
 et al. 14 de nitely paves the way for further 
research in the field of lymphatics in 
chronic renal disease. Novel therapeutic 
interventions aiming at the modulation of 
growth and proliferation of lymphatic cells 
may lead to better treatment modalities and 
understanding of chronic renal disease. 
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 Regulation of renal arteriolar tone 
by adenosine: novel role 
for type 2 receptors 
 Tracy D.  Bell 1 and  William J.  Welch 1 
 Tubuloglomerular feedback regulation of glomerular filtration rate 
(GFR) is mediated by adenosine, which acts on type 1 receptors in the 
afferent arteriole to increase resistance. However, new findings in 
isolated mouse tissue suggest that adenosine also dilates the efferent 
arteriole, which would reinforce the ability of adenosine to reduce GFR. 
This new information extends the concept that adenosine acts as a 
paracrine agent on both afferent and efferent arterioles. 
 Kidney International (2009)  75, 769 – 771.  doi: 10.1038/ki.2009.18 
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 Regulation of glomerular  ltration is a 
critical element of the homeostatic func-
tion of the kidney to maintain stable 9 uid 
and electrolyte balance. Much of this regu-
lation is dependent on the control of the 
renal arterioles surrounding the glomeru-
lar capillary. * e study by Al-Mashhadi 
et al. 1 (this issue) provides new informa-
tion and clarification of a potentially 
important mechanism that targets e: erent 
arteriolar tone. The authors show that 
adenosine acting on type 2 receptors 
dilates the e: erent arteriole. * is provides 
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another component to the complex regu-
lation of glomerular  ltration. 
 Adenosine is formed primarily by 
hydrolysis of adenosine triphosphate 
(ATP), is released from cells, and acts as a 
paracrine agent in several organ systems. 
Adenosine regulates vascular tone by acti-
vation of G protein-coupled purine recep-
tors A 1 (A 1 AR), A 2a (A 2a AR), and A 2b 
(A 2b AR), all commonly expressed in vas-
cular smooth muscle cells. Activation of 
A 1 ARs induces vasoconstriction by inhi-
bition of adenylate cyclase and reduction 
of cyclic adenosine monophosphate 
(cAMP) in smooth muscle cells. Activa-
tion of A 2 ARs produces vasodilation by 
stimulating adenylate cyclase to increase 
cAMP. * erefore the net e: ect of adenos-
ine depends on the receptor type expressed 
in the respective resistance vessel. In most 
vascular beds, A 2 AR expression predom-
inates, and the net e: ect of adenosine is 
vasodilation. However, A 1 ARs, as well as 
A 2 ARs, are abundantly expressed in the 
kidney, yet the net e: ect of adenosine in 
the kidney is to constrict. Systemic infu-
sion of adenosine or selective A 1 AR ago-
nists reduced renal blood 9 ow (reviewed 
by Nishiyama  et al. 2 ). But the kidney is a 
prime example of the signi cance of dif-
ferential expression of these receptors. 
Both the a: erent arteriole, leading to the 
glomerular capillary, and the e: erent arteri-
ole, arising from the glomerular capillary, 
provide the necessary resistance to maintain 
sufficient hydrostatic pressure of the 
glomerular capillary (P GC ) for  ltration. 
 Renal blood flow is maintained by a 
combination of myogenic changes in renal 
resistance vessels and by tubuloglomeru-
lar feedback (TGF). TGF, which may be 
relatively more important, is mediated by 
adenosine released from the epithelial 
cells of the macula densa, which act on 
A 1 ARs in the a: erent arteriole. * erefore, 
gradations of adenosine release, deter-
mined by relative Na   +   load to the macula 
densa and cell Na   +   uptake, dictate the 
tone of this vessel. A 1 ARs are highly 
expressed in the a: erent arteriole, which 
also expresses A 2 ARs. * is relationship 
has been established from numerous stud-
ies focusing on the role of adenosine in 
the mediation of TGF. 3 – 5 * e role of the 
e: erent arteriole is less well understood. 
More important, the balance between 
a: erent and e: erent resistances may be 
critical in the regulation of glomerular 
 ltration rate (GFR). * is balance between 
the two arterioles is not fully understood 
and continues to be a source of investiga-
tion. It is intuitive that increased resistance 
in either arteriole reduces total renal blood 
flow. However, differential or relative 
resistances can lead to various e: ects on 
renal blood 9 ow and, subsequently, GFR. 
When the a: erent arteriole resistance is 
high, P GC is reduced. However, this e: ect 
might be tempered if the e: erent resist-
ance were reduced. Conversely, decreased 
e: erent resistance also reduces GFR. 
 Adenosine is now recognized as a medi-
ator of TGF regulation of GFR, primarily 
via its e: ects on the a: erent arteriole. 5 
TGF is absent in mice de cient in A 1 AR. 3,4 
However, the afferent arteriole also 
expresses A 2 ARs, which may o: set the 
A 1 -mediated constriction, especially in 
juxtamedullary nephrons. 6 Feng and 
Navar showed that afferent arteriolar 
autoregulation was dependent on both 
A 1 AR and A 2 AR in these nephrons. 6 
Using a similar blood-perfused juxtamed-
ullary preparation, Nishiyama  et al. 7 
showed that high adenosine (10  – 5  M ) 
constricted both a: erent and e: erent arte-
rioles, but at even higher doses constric-
tion was lower, suggesting activation of 
A 2 ARs. When they blocked A 1 ARs, ade-
nosine dilated both vessels, suggesting 
functional A 1 ARs and A 2 ARs in both 
vessels. In isolated rabbit e: erent arteri-
oles with adherent tubular segments, Ren 
 et al. 8 showed that increasing macula 
densa sodium chloride caused TGF-medi-
ated dilation, and this response was 
dependent on Ca   +   +   and conversion of 
ATP to adenosine. * ese studies show that 
e: erent arterioles dilate in response to 
adenosine in rat juxtamedullary glomeruli 
and in isolated rabbit glomeruli via A 2 AR, 
but they do not exclude a role for A 1 ARs. 
 Al-Mashhadi  et al. 1 (this issue) con rm 
that adenosine mediates dilation in the 
efferent arterioles in mice and may 
participate in regulation of GFR. * ey used 
isolated e: erent arterioles from mice and 
tested various adenosine agonists and antag-
onists. They show that adenosine or the 
speci c A 1 AR agonist cyclohexyladenosine 
failed to constrict the e: erent arteriole over 
a large dose range, thus contradicting the 
results shown in rat juxtamedullary e: erent 
arterioles. Further, they show that in 
pre-constricted preparations, adenosine and 
the selective A 2 AR agonist 5  - N -ethylcar-
boxamide-adenosine (NECA) dilated the 
efferent arterioles. These effects were 
blocked by the A 2 AR antagonist 3,7-dime-
thyl-1-proparglyxanthine (DMX). * ese 
results demonstrate that the e: erent arteri-
ole in the mouse dilates in response to ade-
nosine. Additionally, this study helps to 
de ne a complementary role for e: erent 
arteriole dilation during A 1 -induced con-
striction in the a: erent arteriole to further 
reduce GFR in response to TGF activation 
by adenosine release. 
 However, this study also introduces new 
concerns about the relationship between 
the A 1 AR and the A 2 AR. * e mouse e: er-
ent arteriole expresses A 1 ARs, yet they 
appear to be inactive, as neither adenosine 
nor cyclohexyladenosine altered the 
vascular tone. * is contradicts studies in 
isolated rabbit e: erent arterioles and in the 
 in vivo rat kidney, and further studies may 
be needed to understand the roles of these 
additional adenosine receptors. 
 Further, the study by Al-Mashhadi 
 et al. 1 suggests that regulation of the e: er-
ent arteriole perhaps is even more com-
plex, since four subtypes of the adenosine 
receptors are expressed. Ultimately the 
net dilating e: ect in this vessel occurs 
despite expression of A 1 ARs. * e authors 











 Figure 1 |  Proposed pathway for adenosine 
activating receptors in afferent and efferent 
arterioles . 
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adenosine acts on the e: erent arteriole, via 
A 2 AR, to dilate this segment. * is would 
result in reduced P GC and thus lower the 
GFR. This represents a supplementary 
mechanism to lower GFR in addition to the 
well-established A 1 AR e: ect in the a: erent 
arteriole. * erefore, activation of adenosine 
release, which is linked to the increased 
solute delivery, would act at two di: erent 
vascular sites. * e e: ects of adenosine on 
these vessels are dependent on the receptors 
expressed in each arteriole. 
 How does this new information add 
to the concept that adenosine regulates 
TGF, vascular tone, and ultimately glomeru-
lar filtration under normal conditions? 
Static input to the macula densa of solute 
load activating the Na   +   / K   +   / 2Cl   −   (NKCC) 
transporter requires generation of ATP via 
Na   +   / K   +   ATPase on the basolateral mem-
branes. Inter- and extracellular nucleotidases 
form adenosine that acts on receptors in the 
vascular bed. The relative expression of 
A 1 AR versus A 2 ARs will dictate the vascular 
response. * erefore, small changes to solute 
input result in sensitive changes in vascular 
tone. * ese new data from Al-Mashhadi 
 et al. 1 support the concept that adenosine is 
signaling to both arterioles, with the same 
e: ect to reduce GFR ( Figure 1 ). 
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 Left ventricular hypertrophy 
in renal disease: 
beyond preload and afterload 
 Eberhard  Ritz 1 
 To explain ventricular concentric and / or eccentric hypertrophy in 
chronic kidney disease, past studies suggested that this was the result of 
increased preload and / or afterload. Using a renal ablation model of the 
mouse with documented absence of hypertension, Siedlecki  et al. 
provide evidence for the involvement of the mammalian target of 
rapamycin (mTOR) pathway. This suggests that load-independent 
primary stimuli trigger or contribute to ventricular hypertrophy and 
fibrosis in uremia. 
 Kidney International (2009)  75, 771 – 773.  doi: 10.1038/ki.2009.35 
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 Since the seminal observation of Richard 
Bright (1789 – 1858), cardiac hypertrophy 
has been known as a characteristic 
component of chronic kidney disease. 
In addition, the brilliant experimental 
studies of Traube (1818 – 1876) docu-
mented that renal damage is associated 
with hypertension as the putative cause of 
cardiac hypertrophy. But is hypertension 
and hypervolemia all there is to cardiac 
hypertrophy in chronic kidney disease? 
 * e past simple concept that cardiac 
hypertrophy in uremia is the result of 
increased a4 erload and preload is no 
longer consistent with the result of an 
experimental study: after subtotal 
nephrectomy, increased dry weight and 
calcium content were documented for the 
right ventricle and for the le4  ventricle 
even when intra-arterial blood pressure in 
conscious animals was normal and when 
sympathetic overactivity, anemia, hyper-
parathyroidism, and so on were pre-
vented. 1 The involvement of the right 
ventricle points to some  systemic factor. 
Interestingly, changes in the isomyosin 
pattern were noted as well. 
 * ere is an ongoing discussion in cardi-
ology about whether physiological hyper-
trophy (as an adaptive response to growth 
signals) di: ers from pathological hyper-
trophy (developing in response to stress 
signals such as increased pre- and a4 er-
load). 2 This is more than an academic 
issue because, as Frey  et al. 2 have pointed 
out, it raises the question of whether car-
diac hypertrophy per se might become a 
potential therapeutic target. 
 Researchers have identified a spec-
trum of signaling pathways that play a role 
in the genesis of di: erent forms of cardiac 
hypertrophy, 2,3 mainly:  
 
     i.  The calcium calcineurin / NFAT 
(nuclear factor of activated T cells) 
pathway; 
   ii.  * e pathway mediated via G pro-
tein-coupled receptors, that is, 
adrenergic, angiotensin, and 
endothelin signals; 
 iii.  * e phosphoinositide 3-kinase / Akt 
(protein kinase B) / glycogen syn-
thase kinase-3 pathway; 
   iv.  Peroxisome proliferator-activated 
receptor (PPAR); 
     v.  * e small G-protein pathway (Rho 
family). 
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